mycophenoloyl chloride | 111512-13-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异香豆素
• 英文名称: mycophenoloyl chloride
• 英文别名: E-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid chloride；6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxoisobenzofuran-5-yl)-4-methyl-4-hexenoyl chloride；(E) 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxoisobenzofuran-5-yl)-4-methyl-4-hexenoyl chloride；mycophenolic acid chloride；(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoyl chloride
• CAS: 111512-13-1
• 化学式: C₁₇H₁₉ClO₅
• 分子量: 338.788
• InChiKey: IESYHSYFTWWOGF-RUDMXATFSA-N

物化性质

• 沸点：
  558.9±50.0 °C(Predicted)
• 密度：
  1.292±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  mycophenoloyl chloride 在 羟胺 作用下， 以 乙腈 为溶剂， 反应 2.0h， 以357 mg的产率得到Mycophenolic hydroxamic acid
  参考文献：
  名称：

  Dual Inhibitors of Inosine Monophosphate Dehydrogenase and Histone Deacetylases for Cancer Treatment

  摘要：

  Mycophenolic acid (MPA), an inhibitor of IMP-dehydrogenase (IMPDH), is used worldwide in transplantation. Recently, numerous studies showed its importance in cancer treatment. Consequently, MPA entered clinical trials in advanced multiple myeloma patients. Suberoylanilide hydroxamic acid (SAHA), a potent differentiation agent acting through inhibition of histone deacetylases (HDACs), was recently approved for treatment of cutaneous T cell lymphoma. We report herein the synthesis of dual inhibitors of IMPDH and HDACs. We found that mycophenolic hydroxamic acid (9, MAHA) inhibits both IMPDH (K-i = 30 nM) and HDAC (IC50 = 5.0 mu M). A modification of SAHA with groups known to interact with IMPDH afforded a SAHA analogue 14, which inhibits IMPDH (K-i = 1.7 mu M) and HDAC (IC50 = 0.06 mu M). Both MAHA (IC50 = 4.8 mu M) and SAHA analogue 14 (IC50 = 7.7 mu M) were more potent than parent compounds as antiproliferation agents. They were also significantly more potent as differentiation inducers.

  DOI：

  10.1021/jm070864w
• 作为产物：
  描述：

  6-(4-羟基-6-甲氧基-7-甲基-3-氧代-5-邻苯二甲酰基)-4-甲基-4-己烯酸三乙胺盐 在 氯化亚砜 作用下， 以 乙酸乙酯 为溶剂， 反应 2.0h， 生成 mycophenoloyl chloride
  参考文献：
  名称：

  [EN] IMPROVED PROCESS FOR PREPARING MYCOPHENOLATE MOFETIL
  [FR] PROCÉDÉ AMÉLIORÉ DE PRÉPARATION DE MYCOPHÉNOLATE DE MOFETIL

  摘要：

  公开号：

  WO2009096668A3

文献信息

• 一种磷酰胺衍生物及制备方法和用途
  申请人：四川海思科制药有限公司

  公开号：CN109305989B

  公开（公告）日：2021-02-26

  本发明涉及一种通式(I)所示化合物及其立体异构体或药学上可接受的盐，以及在制备用于预防或治疗糖尿病、抗肿瘤、多动运动障碍、运动神经元疾病、脑保护、与中枢神经系统相关疾病、免疫抑制、器官组织或细胞异体抑制排斥反应、免疫调节和/或炎性疾病、惊厥、癫痫或脑卒中药物中的应用，通式(I)化合物的结构为Q‑L‑R1，其基团定义与说明书定义一致。
• 5-substituted derivatives of mycophenolic acid
  申请人：Syntex (U.S.A.) Inc.

  公开号：US05493030A1

  公开（公告）日：1996-02-20

  The disclosed hexenoic acid side-chain derivatives of mycophenolic acid are therapeutic agents advantageous in the treatment of disease states indicated for mycophenolic acid and/or mycophenolate mofetil, including immune, inflammatory, tumor, proliferative, viral or psoriatic disorders.

  揭示的己烯酸侧链衍生物是治疗代理，有利于治疗与己烯酸和/或麦考酚酯有关的疾病状态，包括免疫、炎症、肿瘤、增殖、病毒或银屑病等疾病。
• [EN] PROCESS FOR PREPARING MYCOPHENOLATE MOFETIL<br/>[FR] PROCÉDÉ DE PRÉPARATION DE MYCOPHÉNOLATE MOFÉTIL
  申请人：CADILA HEALTHCARE LTD

  公开号：WO2009084008A1

  公开（公告）日：2009-07-09

  The present invention relates to an improved and efficient process for the preparation of Mycophenolate Mofetil in a high degree of pharmaceutically acceptable purity, which comprises the reaction of Mycophenolic acid or esters, or acid chlorides, or amides with metal salt of morpholino ethanol. A further aspect of the invention relates to the purification of Mycophenolate mofetil through salt formation and release of the free base which on recrystalized from suitable solvents to get highly pure Mycophenolate mofetil. The present invention provided a novel intermediate and process for preparation thereof. Also provided is new impurity of Mycophenolate mofetil and process for preparation thereof.

  本发明涉及一种改进和高效的制备高度符合药用纯度的麦考酚酯的过程，其中包括将麦考酚酸或酯、酸氯化物或酰胺与吗啡啶乙醇的金属盐反应。本发明的另一个方面涉及通过盐形成和释放游离碱来纯化麦考酚酯，然后通过适当溶剂的再结晶获得高纯度的麦考酚酯。本发明提供了一种新颖的中间体和其制备方法。还提供了麦考酚酯的新杂质及其制备方法。
• USAGE OF MYCOPHENOLATE MOFETIL OR SALT THEREOF IN PREPARING DRUG FOR RESISTING AGAINST INFLUENZA VIRUS
  申请人：GIANT FORCE TECHNOLOGY CORPORATION

  公开号：US20160052905A1

  公开（公告）日：2016-02-25

  The present invention relates to a use of mycophenolate mofetil or a pharmaceutically acceptable salt thereof in the manufacture of a medicament against influenza virus. The present invention also relates to a use of mycophenolate mofetil or a pharmaceutically acceptable salt thereof in the manufacture of a medicament against drug-resistant influenza virus strains. The present invention is further related to a method for treating influenza in a subject, comprising administering to said subject an effective amount of mycophenolate mofetil or a pharmaceutically acceptable salt thereof.

  本发明涉及将霉酚酸酯酯或其药用盐用于制备用于抗流感病毒的药物。本发明还涉及将霉酚酸酯酯或其药用盐用于制备用于抗耐药流感病毒株的药物。本发明还涉及一种治疗受试者流感的方法，包括向该受试者施用有效量的霉酚酸酯酯或其药用盐。
• Treatment of autoimmune inflammatory, and psoriatic diseases with
  申请人：Syntex (U.S.A.) Inc.

  公开号：US05177072A1

  公开（公告）日：1993-01-05

  Heterocyclic aminoalkyl esters of mycophenolic acid, and the derivatives and pharmaceutically acceptable salts thereof, are useful as immunosuppressive agents, anti-inflammatory agents, anti-tumor agents, anti-viral agents, and anti-psoriatic agents.

  甲氧苯酸的杂环氨基烷基酯及其衍生物和药用盐，可用作免疫抑制剂、抗炎剂、抗肿瘤剂、抗病毒剂和抗银屑病剂。